1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Stenocare A/S

Stenocare A/S

STENO.CO
Stenocare A/SDK flagNASDAQ Copenhagen
1.00
DKK
+0.01
- -
43.20MMarket Cap
Stenocare A/S
STENO.CO
(NASDAQ Copenhagen)

Recent

price

1.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.23
0.27
- -
0.07
0.19
0.15
0.06
0.18
0.08
Revenue per Share
-0.18
0.09
-0.59
-0.57
-0.7
-0.7
-0.96
-0.06
-0.8
Basic EPS, GAAP
-0.31
-0.61
-1.57
-0.75
-0.69
-0.41
-0.2
-0.18
-0.15
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.14
0.75
2.63
1.82
1.04
1.03
-0.1
0.24
0.06
Book Value per Share
1.14
0.75
2.63
1.82
1.04
1.03
-0.1
0.05
0.06
Tangible Book Value per Share
18
18
20
22
23
25
36
40
36
Basic Weighted Avg Shares
4
5
- -
2
4
4
2
7
3
Sales/Revenue/Turnover
-86.67
88.19
- -
-893.9
-368.11
-424.32
172.75
-25.26
-527.28
Operating Margin (%)
- -
- -
- -
1
3
3
9
- -
7
Depreciation Expense
-3
2
-12
-13
-16
-18
-34
-2
-29
Net Income, GAAP
- -
24.22
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-79.05
34.45
- -
-808.38
-363.1
-467.54
-1,545.07
-34.05
-1,029.89
Profit Margin (%)
20
5
26
13
4
4
-2
2
3
Working Capital
- -
- -
- -
1
5
1
2
- -
1
LT Debt
20
13
53
40
24
26
-3
9
2
Total Equity
- -
19.07
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
60.52
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-35.69
-27.44
-50.64
-70.33
- -
- -
-281.87
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1
1
2
LT Borrowings
2
2
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
38
38
Market Capitalization
24
13
20

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
5
9
9
Cash, Cash Equivalents & STI
1
6
5
Accounts Receivable, Net
1
1
2
Inventories
- -
1
- -
Total Current Liabilities
7
5
5
Payables & Accruals
- -
- -
- -
ST Debt
1
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-108.53%
-372.71%
Free Cash Flow
- -
-23.23%
0.26%
Net Income, GAAP
- -
9.41%
-93.07%
Sales/Revenue/Turnover
- -
54.92%
214.54%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
-1
1
2
2025
1
2
3
- -
7
2026
3
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.11
-0.11
-0.14
-0.62
-0.96
2025
-0.05
- -
- -
- -
-0.06
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
ETHZilla Corporation Warrant (ATNFW)
Hindustan Bio Sciences Limited (HINDBIO.BO)
Bharat Immunologicals & Biologicals Corporation Limited (BIBCL.BO)
Leafly Holdings, Inc. (LFLY)
MedAvail Holdings, Inc. (MDVL)
Holy Stone Healthcare Co., Ltd. (4194.TWO)
Business
Stenocare A/S is a Danish pharmaceutical company specializing in the development, import, and sale of prescription-based medical cannabis oil products. Founded in 2017 and headquartered in Randers, Denmark, the company produces a portfolio of 13 pharmaceutical-grade cannabis oils, including THC, CBD, and THC/CBD combination oils, designed for the treatment of pain, multiple sclerosis, epilepsy, nausea associated with chemotherapy, and opioid addiction. Stenocare operates in Northern Europe and Australia, with key markets in Denmark, Sweden, Norway, Germany, the United Kingdom, and Australia, supplying these products under strict regulatory approvals. The company recently undertook a major strategic shift under its STENOCARE 3.0 strategy, transitioning from cultivation and production to focusing on trading and distribution of finished medical cannabis products. This transition included exiting its cultivation facility in Denmark to reduce operational costs significantly, relocating its headquarters to Copenhagen, and reinforcing its distribution network. Stenocare has developed innovative products such as the patented Astrum cannabis oil line, launched ahead of schedule in Australia and approved for sale in Norway and Denmark, featuring enhanced bioavailability for improved patient outcomes. The company also acquired CannGros ApS in late 2025 to bolster its market position and add annual revenue, supporting its goal of achieving break-even by 2026. Stenocare’s offerings encompass a range of medical cannabis oils sold under its proprietary brands, utilizing pharmaceutical quality standards and patented oil technologies. The company caters primarily to patients requiring prescription medical cannabis under national healthcare programs and collaborates with healthcare providers through platforms including an IT-enabled online clinic to facilitate patient access. Stenocare continues to pursue new market entries and innovations in product development while maintaining a leading position in its core Nordic and Australian markets.